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Although group 3 innate lymphoid cells (ILC3s) are efficient inducers of T cell responses in
the spleen, they fail to induce CD4+ T cell proliferation in the gut. The signals regulating
ILC3-T cell responses remain unknown. Here, we show that transcripts associated with MHC
II antigen presentation are down-modulated in intestinal natural cytotoxicity receptor (NCR)−
ILC3s. Further data implicate microbiota-induced IL-23 as a crucial signal for reversible
silencing of MHC II in ILC3s, thereby reducing the capacity of ILC3s to present antigen to
T cells in the intestinal mucosa. Moreover, IL-23-mediated MHC II suppression is dependent
on mTORC1 and STAT3 phosphorylation in NCR− ILC3s. By contrast, splenic interferon-γ
induces MHC II expression and CD4+ T cell stimulation by NCR− ILC3s. Our results thus
identify biological circuits for tissue-specific regulation of ILC3-dependent T cell responses.
These pathways may have implications for inducing or silencing T cell responses in human
diseases.
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ILC3s are primarily tissue-resident cells, which rapidly respondto infections and inflammation by cytokine secretion. Theyexpress and depend on the transcription factor RAR-related
orphan receptor gamma t(RORγt)1,2 and can be subdivided into
natural cytotoxicity receptor (NCR)+ and NCR− cells3. Similar to
T helper (TH)22 and TH17 cells, ILC3s secrete interleukin (IL)-
22 and IL-174–6 and play a role in defense against Citrobacter
rodentium infection and in tissue regeneration7–11. In addition to
their function as early cytokine producers, recent analysis has
revealed that ILC3 subsets can present antigen (Ag) to CD4+
T cells, but the quality and strength of T-cell response is tissue-
dependent12–14. How ILC3-T-cell responses are regulated
remains poorly defined.
In adults, ILC3s are abundant in mucosal tissues, e.g., the small
intestine (SI) and colon, and mucosa-associated lymphoid
organs3,15. In addition, ILC3s are found in the spleen (SP) and
peripheral lymph nodes6,15. It is now increasingly recognized that
ILCs exhibit heterogenous phenotypes across different tissues16–19.
The exposure to environmental signals including microbial and
nutrient-derived metabolites has been suggested to be relevant for
the regulation of IL-22 and IL-17 responses of intestinal
ILC3s7,20–23. The nature of signals that regulate Ag presentation
and T-cell stimulation by ILC3s, however, is largely unknown.
Moreover, data on a direct comparison of ILC3s among different
organs are limited and often based on a sorting strategy not
considering subsets. Single-cell transcriptome profiling of SI ILCs
revealed that major histocompatibility complex (MHC) class II
(MHC II) is mainly found in a NCR− ILC3 subset that lacks the
T-box transcription factor T-bet (encoded by Tbx21) and is only
partially overlapping with IL-22-producing ILC3s20. In the SP,
Ag-presenting NCR− ILC3s elicit specific CD4+ T-cell responses
and support the maintenance of CD4+ memory T cells14,24. In
the SI, however, MHC II+ ILC3s are considered as negative
regulators of commensal bacteria-specific CD4+ T-cell
responses12,13,25. A central question that has not been addres-
sed concerns the tissue-specific signals that regulate the capacity
of ILC3 subsets to present Ag to CD4+ T cells.
We demonstrate here that NCR− ILC3s isolated from the SP
and the SI of mice have a fundamentally distinct transcriptional
signature. SP NCR− ILC3s harbor MHC II+ ILC3s with the
capacity to elicit cognate CD4+ T-cell responses. In contrast, the
majority of SI NCR− ILC3s lack MHC II and fail to induce T-cell
proliferation. This is due to the fact that the gut microbiota and
IL-23 inhibit the expression of MHC II on ILC3s via pathways
engaging mammalian target of rapamycin complex 1 (mTORC1)
and signal transducer and activator of transcription 3 (STAT3).
On the contrary, interferon γ (IFN-γ) enhances the expression of
MHC II on ILC3s in the SP. Finally, we show that the functional
inhibition of ILC3s by the SI environment is reversible both
in vitro and in vivo. Together our data uncover the basic mole-
cular requirements of ILC3s to control T-cell responses and
highlight the role of the local environment in shaping tissue-
specific ILC3-T-cell interactions.
Results
SP and SI ILC3s have a different transcriptional signature. SP
and SI ILC3s differ in their capacity to induce Ag-dependent
CD4+ T-cell responses12,14. To study the tissue-specific regula-
tion of SP vs. SI NCR− ILC3 transcriptional programs, we pro-
filed the transcriptome of the two subsets. To this end, lin
−CD117+Thy1.2+eYFP+ cells from SP and SI of RORc(γt)-Cretg
Rosa26ReYFP/+ (Rorγtfm+) mice were sort-purified and subjected
to RNA-sequencing (Supplementary Fig. 1a). The principal
component analysis (PCA) of SP and SI NCR− ILC3s revealed a
different transcriptional profile of the two subsets (Fig. 1a). A
total set of 1286 genes was differentially expressed with specific
signature of SP and SI ILC3s for genes encoding transcription
factors (e.g., Epas1, Arnt2, or Runx1t1), cytokines (e.g., Il22 and
Il17a) and genes involved in IL-23, hypoxia, or IFN-α responses
(Fig. 1b, c, Supplementary Fig. 1b, c). Importantly, transcripts
relevant for MHC II-dependent Ag presentation and costimula-
tion (e.g., H2-Aa, H2-Ab, Cd74, Cd80, Cd86, and Ctse) were
enriched in SP ILC3s (Fig. 1d). Flow cytometry analysis con-
firmed the enhanced expression of MHC II, CD80, and CD86 of
SP NCR− ILC3s (Fig. 1e). A subset of naive MHC II+ and MHC
II−NCR− ILC3s produced IL-22 (Supplementary Fig. 1d). In line
with previous publications only the C-C chemokine receptor type
6 (CCR6)+ subset of NCR− ILC3s expressed MHC II (Supple-
mentary Fig. 1d)12,20.
SP and SI ILC3s differ in their capacity to activate T cells. As
transcripts required for Ag presentation were enriched in SP
ILC3s, we measured the capacity of activated SP and SI ILC3s to
process and present Ag and to induce CD4+ T-cell activation and
proliferation. SP and SI NCR− ILC3s from Rag2−/− mice (Sup-
plementary Fig. 2a, b) and bone marrow-derived dendritic cells
(BMDCs) as positive control were stimulated with IL-1β and
cultured in the presence of Ovalbumin (Ova) protein or peptide
with Ova-specific T-cell receptor (TCR) transgenic CD4+ T cells
(OT-IItg CD4+ T cells). Pre-activation of Ag-presenting cells
(APCs) was chosen to simulate immunogenic conditions under
which T-cell responses toward foreign Ag are elicited in vivo. IL-
1β boosts the capacity of SP ILC3s to induce T-cell responses
in vitro by upregulation of CD80, CD86 and MHC II14. IL-1β also
induced the expression of Tnfsf4 and its product OX40L by SP
and SI ILC3s (Supplementary Fig. 2c, d).
In the presence of either Ova protein or peptide SP NCR−
ILC3s induced significant CD69 upregulation and proliferation of
OT-IItg CD4+ T cells (Fig. 2a, b). Only a weak T-cell proliferation
was observed with SI ILC3s and Ova protein, whereas almost 50%
of T cells proliferated with Ova peptide. The observed difference
between SP and SI NCR− ILC3s might be explained by two
potential mechanisms: (I) SI NCR− ILC3s are less efficient at Ag
uptake and processing and/or (II) NCR− ILC3s with properties of
APCs are enriched in the SP. The finding that a higher percentage
of freshly isolated SP NCR− ILC3s expressed MHC II, CD80, and
CD86 as compared with SI NCR− ILC3s (Fig. 1e) supports the
latter hypothesis. To explore this further, we studied the protein
processing capacity of MHC II+ and MHC II− NCR− ILC3s from
the SI and the SP (Fig. 2c). For this purpose, ILC3s from Rag2−/−
mice were cultured with Eα-GFP protein. Eα-peptide presented
by MHC II molecules was detected by staining with the antibody
clone YAe. As expected the YAe antibody did not stain MHC II−
ILC3s. Interestingly, comparable frequencies of SI and SP MHC II+
NCR− ILC3s presented the Eα peptide. Sort-purified SP and SI
MHC II+ ILC3s were also equally efficient at inducing T-cell
activation and proliferation in the presence of Ova protein
(Fig. 2d and Supplementary Fig. 2e). MHC II− SP ILC3s were
superior of MHC II− SI ILC3s at inducing T-cell activation, most
likely because IL-1β stimulation induced MHC II expression in
MHC II−-sorted SP ILC3s, but not in SI ILC3s (Supplementary
Fig. 2f)14. Together these data demonstrate that both SP and SI
harbor a MHC II+ ILC3 subset that equally processes and
presents Ag and induces proliferation of CD4+ T cells.
Furthermore, this subset is significantly enriched in SP NCR−
ILC3s ex vivo and after in vitro stimulation with IL-1β.
Since Ova protein pulsed DCs exceeded ILC3s in their capacity
to induce T-cell proliferation (Fig. 2a, b), we asked whether DCs
and ILC3s also differ in the quality of T-cell responses. Therefore,
the cytokine production of OT-IItg CD4+ T cells in co-cultures
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with pre-activated DCs, SP ILC3s and SI ILC3s was measured.
T cells stimulated with ILC3s produced less IFN-γ and more TNF
(Supplementary Fig. 2g) as compared with co-cultures with Ag-
pulsed DC. The IL-22 secretion of T cells was comparable when
ILC3s or DCs were added as APCs (Supplementary Fig. 2g).
It has been previously reported that naive SI ILC3s induce T-
cell death of commensal bacteria-specific T cells at steady state13.
We therefore performed a SI ILC3-CD4+ T cell assay and
incubated T cells with Annexin V which stains apoptotic cells.
The percentage of Annexin V+ OT-IItg CD4+ T cells after co-
culture with IL-1β-pre-activated SI ILC3s and Ova Ag was
reduced as compared with controls without Ova (Supplementary
Fig. 2h). It is hence possible that the activation state and the type
of Ag determine the effect of ILC3s on T-cell death.
Tissue localization determines the APC phenotype of ILC3s. To
analyse whether the APC properties of ILC3s are fixed or can be
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altered by environmental signals, SP and SI ILC3s from Rorγtfm+
Rag2−/− mice were adoptively transferred into Rag2−/−Il2rg−/−
mice. Five weeks after transfer, eYFP+ donor ILC3s isolated from
the SP and the SI of recipient mice were analyzed for the
expression of CD80, CD86, CD74, and MHC II. There was no
tissue-origin-specific bias of ILC3s homing to SP and SI.
Importantly, SP donor ILC3s isolated from the SI of recipients
had down-modulated CD80, CD86, CD74, and MHC II (Fig. 3a).
Conversely, SI donor ILC3s isolated from the SP of recipients
had upregulated these molecules (Fig. 3b). Similar results were
obtained 7 days after adoptive transfer of total splenocytes
or intestinal lymphocytes into Rag2−/−Il2rg−/− mice
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(Supplementary Fig. 3a, b). In addition, the retention marker
CD69 was downregulated in SI ILC3s after migration to the SP
and upregulated in SP ILC3s after migration to the SI.
In order to test if retention or survival of MHC II+ ILC3s was
superior in the SP, SI CD45.1+MHC II− and SI eYFP+MHC II+
ILC3s were injected into Rag2−/−Il2rg−/− mice (Supplementary
Fig. 3c, d). Five weeks later the two donor cell subsets were
discriminated by anti-CD45.1 staining and eYFP. The input ratios
of donor ILC3 subsets did not differ from the ratios in recipient
SP. This strongly suggests that MHC II+ and MHC II− ILC3s
were comparable in retention or survival in the SP (Supplemen-
tary Fig. 3d). In line with previous results MHC II+ ILC3s lost
MHC II expression in the intestine and MHC II− ILC3s gained
MHC II expression in the SP (Supplementary Fig. 3e).
Altogether the SI environment suppressed the expression of
molecules required for MHC II Ag presentation and T-cell
activation. Our data suggest that NCR− ILC3s exhibit certain
plasticity and that tissue-specific factors condition the capacity of
ILC3s to act as APCs for CD4+ T cells.
In vitro culture reverses functional polarization of ILC3s. Our
in vivo data showed that SI NCR− ILC3s, when migrating to the
SP, upregulated molecules required for Ag presentation and
activation of CD4+ T cells. To further explore their plasticity,
sort-purified SI ILC3s from Rag2−/− mice were cultured with IL-
2, IL-7, and stem cell factor (SCF) for 7 days and used for RNA
sequencing, flow cytometric analysis and stimulation of OT-IItg
CD4+ T cells. PCA of RNA sequencing data showed that samples
from cultured SI ILC3s clustered with freshly isolated (ex vivo) SP
ILC3 samples (Fig. 4a). Importantly, transcripts associated with
MHC II Ag presentation were upregulated in SI ILC3s after
culture (Fig. 4b). In addition, in vitro culture of SI ILC3s resulted
in increased MHC II protein expression and accumulation of a
CD74+ MHC II+ population of NCR− ILC3s, a subset existing
only at low frequency within ex vivo SI ILC3s (Fig. 4c). These
data demonstrate that SI ILC3s acquire a SP-like phenotype upon
in vitro culture.
To test the capacity of cultured SI NCR− ILC3s to present Ag
and stimulate CD4+ T cells, ex vivo and cultured SI ILC3s were
incubated with OT-IItg CD4+ T cells and Ova protein (Fig. 4d) or
Ova peptide (Fig. 4e). Our data show that cultured SI ILC3s were
significantly better at CD4+ T-cell stimulation compared with
ex vivo SI ILC3s, suggesting that environmental factors in the
intestine may negatively affect the Ag presentation capacity
of ILC3s.
IL-23 negatively regulates Ag presentation by ILC3s. To
investigate whether microbial products negatively regulated the
capacity of SI ILC3s to induce T-cell responses, ILC3s from germ-
free (GF) mice were assessed for their ability to stimulate CD4+
T cells in vitro and to express MHC II. SI NCR− ILC3s from GF
mice were significantly better at inducing Ova-specific CD4+ T-
cell proliferation in vitro and had a higher expression of MHC II
as compared with NCR− ILC3s from conventional specific
pathogen-free (SPF) mice (Fig. 5a, b and Supplementary Fig. 8).
Together, in the absence of microbiota the capacity of SI ILC3s to
stimulate CD4+ T cells was enhanced.
Interestingly, gnotobiotic sDMDMm2 mice colonized with a
mixture of 12 bacterial strains covering the five major phyla of
procaryotes (see Table 1) showed no increased expression of
MHC II on SI ILC3s as compared with conventional SPF mice,
indicating that these bacteria were sufficient to repress MHC II
expression (Supplementary Figs. 4a and 8)26.
ILC3s isolated from RORc(γt)-CretgMyd88fl/fl(Myd88ILC3−/−)
mice and littermate controls expressed similar MHC II levels
indicating that TLR signaling via MyD88 was not responsible for
downregulation of MHC II (Supplementary Figs. 4b and 8).
Our observations prompted us to study the effect of IL-23 on
MHC II expression of ILC3s, since gut microbes can induce the
expression of IL-23 by dendritic cells (DCs)27. Indeed, Il23p19
expression was significantly higher in the SI compared with the
SP of SPF mice (Supplementary Fig. 5a). In line with a previous
report, the expression of II12b and Il23p19 encoding the subunits
of IL-23 were reduced in the terminal ileum of GF compared with
SPF mice (Fig. 5c)28. To analyse whether IL-23 is involved in
shaping the MHC II+ to MHC II− ratio of NCR− ILC3s in the SI,
IL-23 deficient (Il23p19−/−) mice were used. Interestingly, a
higher percentage of MHC II+ cells was found in SI NCR− ILC3s
of Il23p19−/− compared with wild-type (WT) mice (Fig. 5d and
Supplementary Fig. 8). IL-23 deficiency did not increase the
expression of MHC II on ILC3s in the spleen (Supplementary
Fig. 5b and 8) most likely because IL-23 is not abundant in the
spleen. CD80 and CD86 expression was not significantly affected
by the lack of IL-23 (Supplementary Fig. 5c). SI ILC3s from
Il23p19−/− mice showed a significant increase in their capacity to
induce Ova-specific OT-IItg CD4+ T-cell responses (Fig. 5e and
Supplementary Fig. 5d). Conversely MHC II expression was
reduced in WT SI or SP ILC3s after in vitro culture with IL-23 for
7 days (Fig. 5f). IL-23 also repressed the MHC II expression of SI
ILC3s isolated from Il23p19−/− mice, indicating that ILC3s have
no intrinsic defect in Il23p19−/− mice (Supplementary Fig. 5e).
Finally, IL-23 added to 7 day cultures of SI ILC3s diminished
their capacity to stimulate OT-IItg CD4+ T cells (Fig. 5g,
Supplementary Fig. 5f, g).
Collectively these data suggest that microbe-induced IL-23
negatively affects the capacity of NCR− ILC3s to induce CD4+
T-cell responses.
IL-23 reduces MHC II expression through mTORC1 and
STAT3. mTORC1 and STAT3 have been shown to be activated
in innate immune cells upon IL-23 stimulation29–31. We
therefore asked, whether IL-23-mediated silencing of MHC II in
SI ILC3s requires mTORC1 and STAT3 signaling. IL-23 stimu-
lation of NCR− ILC3s induced phosphorylation of the
mTORC1 signaling kinase S6, mTOR and of STAT3 (Fig. 6a, b
and Supplementary Fig. 6a). When ILC3s were incubated with
Rapamycin or isolated from mice with a conditional deletion of
Rptor in ILC3s (RptorILC3−/−, Rag2−/− background) (Fig. 6a and
Supplementary Fig. 6a), IL-23 failed to activate mTORC1.
Interestingly, the percentage of ex vivo MHC II+ SI NCR− ILC3s
from RptorILC3−/− mice was twice as high as in control mice
(Rptorfl/fl) suggesting that IL-23-mediated mTORC1 signaling
suppressed the expression of MHC II on SI ILC3s (Fig. 6c and
Supplementary Fig. 8). This was confirmed by stimulating SI and
SP ILC3 from RptorILC3−/− mice for 7 days with IL-23 in vitro
(Supplementary Fig. 6b). In the SI of mice with a Stat3 deletion in
hematopoietic cells (VAV1-CretgStat3fl/fl) a significantly higher
percentage of MHC II+ NCR− ILC3s was observed as compared
with control mice (Fig. 6d and Supplementary Fig. 8). Notably,
in vivo deletion of Il23p19, Rptor or Stat3 had no effect on the
MHC II+ NCR− ILC3s percentage in the SP further emphasizing
the fact that MHC II downregulation was specific for the gut
(Supplementary Fig. 8).
It was recently shown that IL-23 promotes dermal γδ T-cell
differentiation and effector functions via STAT3 phosphoryla-
tion independently of the mTOR pathway32. Strikingly, IL-23-
activated ILC3s from RptorILC3−/− mice showed a reduced
STAT3 phosphorylation indicating that in ILC3s the IL-23/
STAT3 axis was partially dependent on mTORC1 (Supplemen-
tary Fig. 6c). Following IL-23-stimulation S6 phosphorylation
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of genes associated with MHC II Ag presentation. c Expression of MHC II and CD74 by cultured ILC3s (n= 5 distinct samples) or ex vivo SI (n= 9–10
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was almost normal in Stat3-deficient ILC3s as compared with
controls indicating that the majority of IL-23-induced
mTORC1 signaling occurs independently of STAT3 (Supple-
mentary Fig. 6d). Together these data demonstrate that the IL-
23-mTORC1-STAT3 axis mediates downregulation of MHC II
in SI ILC3s.
IFN-γ positively regulates MHC II expression of ILC3s.
Adoptively transferred SI ILC3s displayed increased levels of
MHC II in the SP of recipient mice (Fig. 3b). Since the major
transcriptional regulator of MHC II expression is CIITA (class II
MHC transactivator), these results suggest that splenic factors
may induce or intestinal factors may repress CIITA. We therefore
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analyzed the expression of the three mRNA isoforms of the Ciita
gene, which are regulated by different promoters (Fig. 7a)33.
Indeed, freshly isolated SP ILC3s used Ciita promoters pI, pIII,
and pIV, whereas ex vivo isolated SI ILC3s expressed only the pI-
regulated isoform. These data indicate that there is a tissue-
specific regulation of Ciita expression in ILC3s. IL-23 reduced the
expression of promoter pIII in SP ILC3s (Supplementary Fig. 7a).
It is hence possible that the IL-23-dependent repression of MHC
II in vivo and in vitro was at least partially mediated by the
reduction of Ciita pIII.
The promoter pIV, which was expressed in SP ILC3s, is
inducible by IFN-γ33. IFN-γ expression was remarkably higher in
the SP (Fig. 7b) pointing to its potential role in Ciita pIV-driven
MHC II expression of SP ILC3s. To delineate the role of IFN-γ,
we analyzed the expression of MHC II on SP and SI ILC3s of Ifng
−/− mice and after stimulation of SI ILC3s with IFN-γ. SP NCR−
ILC3s had a significantly lower expression of MHC II in Ifng−/−
mice as compared with WT mice (Fig. 7c and Supplementary
Fig. 8). CD80 and CD86 expression levels were not affected
(Supplementary Fig. 7b). Conversely, stimulation with IFN-γ
significantly increased the expression of MHC II molecules and
Ciita promoter pIV by SI NCR− ILC3s (Fig. 7d, e). The effect on
MHC II induction was abolished in cultures containing IFN-γ
and IL-23 suggesting a dominant role of IL-23 in suppressing the
expression of MHC II on ILC3s (Supplementary Fig. 7c). To
analyse if IFN-γ also affects the capacity of ILC3s to stimulate T-
cell responses, SI NCR− ILC3s were incubated with IFN-γ or left
untreated and used for stimulation of CD4+ T cells with Ova
peptide (Fig. 7f). IFN-γ stimulated SI ILC3s were significantly
better at inducing T-cell proliferation as compared with
untreated cells.
In summary, we provide evidence that IFN-γ in the SP
environment increases expression of MHC II molecules on NCR−
ILC3s and enhances their potential to induce CD4+ T-cell
immune responses.
Discussion
We show here that NCR− ILC3s have a tissue-specific tran-
scriptional signature. Transcripts associated with MHC II Ag
presentation are relatively enriched in SP NCR− ILC3s. SP NCR−
ILC3s are significantly more efficient in inducing CD4+ T-cell
activation and proliferation as compared with SI NCR− ILC3s. A
subset of SI MHC II+ NCR− ILC3s, however, can induce Ag-
specific CD4+ T-cell proliferation. The fact that SI ILC3s can
adopt an APC phenotype upon in vitro culture or in vivo
migration to the SP suggests that environmental signals deter-
mine the capacity of ILC3s to present Ag and to stimulate CD4+
T cells. Indeed, we identified two essential pathways regulating
ILC3-T-cell interactions in the SI vs. SP. One is mediated by
microbe-induced IL-23, which supresses MHC II expression of
NCR− ILC3s through mTORC1 and STAT3 activation. The other
pathway involves IFN-γ signaling, which induces the expression
of MHC II on NCR− ILC3s and promotes NCR− ILC3-mediated
CD4+ T-cell activation and proliferation. The IFN-γ induced
MHC II expression of NCR− ILC3s is reflected by the induction
of Ciita pIV expression in ILC3s upon IFN-γ stimulation. The
fact that the IFN-γ expression is low in the SI of WT mice
explains why in Ifng−/− mice no significant reduction of MHC II
expression by SI ILC3s was observed. Likewise, IL-23 expression
is low in the SP and deletion of Il23p19 does not alter MHC II
expression of SP ILC3s.
SI ILC3s were shown to suppress commensal bacteria-specific
T-cell responses12. The discrepancy to our data might be partially
explained by the fact that we studied ILC3 APC function under
activation conditions. Similarly, a study published in this issue
demonstrates that upon activation human ILC3s acquire Ag-
presenting properties for the induction of Ag-specific CD4+
memory T-cell responses34. In mice upon IL-1β-stimulation both
SI and SP ILC3s upregulate OX40L. OX40L has been described to
be essential for the induction of pathogenic T-cell responses by
TL1a-activated ILC3s in chronic colitis35. Our findings indicate
that SI MHC II+ ILC3s do not block CD4+ T-cell immune
responses per se. Under steady-state conditions, however, and
under the local influence of microbiota and IL-23 the frequency
of MHC II+APC-like ILC3s is probably too low to elicit T-cell
responses in the SI. Moreover, our data strongly suggests a
dominant effect of IL-23 in repressing MHC II expression
of ILC3s.
During the early phase of viral infections, innate immune cells
can rapidly release high amounts of IFN-γ. This could result in
the expansion of SP MHC II+ ILC3s localized at the border
between T and B-cell areas36, where Ag uptake and presentation
takes place. Our findings that SI ILC3s upregulate MHC II and
induce CD4+ T-cell proliferation after stimulation with IFN-γ
demonstrate their potential to act as APCs under conditions
where IFN-γ is released, e.g., during infections. Whether this is
sufficient to promote CD4+ T-cell responses in the gut remains to
be investigated.
It has been previously reported that the microbiota promotes
IL-23-induced phosphorylation of STAT3, thereby inducing IL-
22 in ILC3s29. We describe here that microbe-induced IL-23 also
limits the frequency of MHC II+ NCR− ILC3s in the SI. NCR−
ILC3s can be further subdivided into CCR6+ and CCR6− cells.
Interestingly, IL-23 has been shown to promote the development
of T-bet+CCR6−NCR− ILC3s37, which lack MHC II12. Our data
strongly suggest that the IL-23-rich SI environment favors the
accumulation of MHC II− ILC3s, but amongst this subset we
found both CCR6+ and CCR6− ILC3s. IL-23 signaling in NCR−
ILC3s induced mTORC1 activation and STAT3 phosphorylation.
We propose a model in which the collaborative mTORC1 and
STAT3 signaling leads to downregulation of MHC II, most likely
by the reduction of Ciita promoter pIII expression. In addition,
IL-23 signaling may bypass mTORC1 to some extent and activate
STAT3 via Janus kinases (JAK)38. We cannot exclude that other
intestinal factors may prevent NCR− ILC3-mediated CD4+ T-cell
proliferation, in particular by inhibition of costimulatory or
induction of coinhibitory molecules.
ILC3s are mainly tissue-resident cells and therefore exposed to
local signals coming from other immune cell subsets, soluble
factors, metabolites, and microbial products39. Recently, a tissue-
specific imprinting has been reported for group 2 ILCs18 and
group 1 ILCs40. Furthermore, Nussbaum et al. showed that the
tissue environment affects the expression of several surface
markers, e.g., NKp46 and NK1.1, by total ILC3s in SP and SI and
that the SI environment inhibits the capacity of ILC3s to reject IL-
Table 1 Microbial organisms used for sDMDMm2 mice.
Organism DSM no.
Lachnoclostridium sp. YL32 DSM 26114
Ruminiclostridium sp. KB18 DSM 26090
Bacteroides sp. I48 DSM 26085
Parabacteroides sp. YL27 DSM 28989
Burkholderiales bacterium YL45 DSM 26109
Erysipelotrichaceae bacterium I46 DSM 26113
Blautia sp. YL58 DSM 26115
Flavonifractor plautii YL31 DSM 26117
Bifidobacterium animalis subsp. animalis YL2 DSM 26074
Lactobacillus reuteri I49 DSM 32035
Akkermansia muciniphila YL44 DSM 26127
Enterococcus faecalis KB1 DSM 32036
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12 secreting melanomas17. Our study provides a comprehensive
comparison of transcriptomic profiles of NCR− ILC3s uncovering
a tissue-specific signature responsible for Ag presentation and T-
cell stimulation. We show that the ratio of NCR− ILC3 subsets
with and without APC functions depends on IFN-γ and microbe-
induced IL-23.
The discovery that APC properties of ILC3s are controlled by
IFN-γ and microbe-induced IL-23 has important implications for
our understanding of immune regulation in the gut. While the SP
provides cytokines promoting the differentiation of MHC II+
ILC3s that are efficient inducers of T-cell responses, our data
extend the current model in which intestinal T-cell responses are
limited by ILC3s. We propose that under steady-state conditions
microbial commensals trigger constitutive IL-23 production by
mononuclear cells and subsequently reduction of MHC II+ ILC3s
in the SI. Altogether this might be essential to promote tissue
protection and to prevent T-cell-dependent immune responses.
Under chronic inflammatory conditions, however, intestinal
ILC3s may promote pathogenic pro-inflammatory T-cell activa-
tion as previously suggested35. Therefore, tissue-specific altera-
tions of the cytokine repertoire and microbial composition during
infectious or inflammatory diseases should be considered as
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Fig. 6 IL-23 reduces MHC II expression through activation of mTORC1 and STAT3. a Phosphorylation of S6 of SI ILC3s (sorted from Flt3Ltg mice) after
48 h stimulation with or without IL-23 and 0, 10, or 100 nM Rapamycin (red= tubulin and green= p-S6). ILC3s were sorted as depicted in Supplementary
Fig. 2a. Indicated is the relative phosphorylation of S6 (fluorescence signal for p-S6 normalized by fluorescence signal for tubulin). The indicated bar
represents 3 mm. n= 6 distinct samples of five independent experiments. b Phosphorylation of STAT3(Tyr705) of sort-purified SI ILC3s (Supplementary
Fig. 2a) from Rag2−/− mice after 20min stimulation with or without IL-23. n= 4 distinct samples of four independent experiments. c MHC II expression of
SI and SP ILC3s from Rptorfl/flRag2−/− and RptorILC3−/−Rag2−/− mice. NCR− ILC3s were gated as shown in Fig. 1. n= 6 mice of two independent
experiments. d MHC II expression of SI and SP ILC3s from Stat3fl/fl (n= 4 mice) and Vav1-CretgStat3fl/fl (n= 7 mice) mice. NCR− ILC3s were gated as
shown in Fig. 1. Two independent experiments. Each symbol represents a sample and the bar graph represents the mean ± s.e.m. n.s. not significant; **P≤
0.01; ***P≤ 0.001; ****P≤ 0.0001, calculated with one-way ANOVA (two-tailed) and Bonferroni’s multiple comparisons test (a) or two-tailed paired (b) or
two-tailed unpaired (c and d) Student’s t test. Source data are provided as a Source Data File.
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critical factors regulating ILC3-T-cell responses and disease
outcome.
Methods
Antibodies. Fluorescent-labeled or biotin-conjugated antibodies (Abs) were pur-
chased from BioLegend, eBioscience, Cell Signaling Technology, LI-COR Bios-
ciences or BD Bioscience. The following Abs were used anti-CD3ε (145-2C11),
anti-CD4 (RM4-5 or GK1.5), anti-CD8α (53-6.7), anti-CD11b (M1/70), anti-
CD11c (N418), anti-CD19 (6D5), anti-CD45R (RA3-6B2, B220), anti-CD69
(H1.2F3), anti-CD74 (CLIP), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-CD90.2
(Thy1.2, 30-H12), anti-CD117 (2B8), anti-Gr-1 (RB6-8C5, Ly-6G), anti-TCR-β
(H57-597), anti-TCR-γδ (UC7-13D5), anti-TER-119 (TER-119), anti-MHC II
(M5/114.15.2), anti-NKp46 (29A1.4), anti-NK1.1 (PK136), anti-KLRG1 (2F1),
anti-Ea52-68 (ebioYAe), anti-p-STAT3 (Tyr705) (13A3-1), anti-RORγt (AFKJS-9 or
B2D), anti-OX40L (RM134L), anti-IFN-γ (XMG1.2), anti-TNF (MP6-XT22), anti-
IL-22 (1H8PWSR), anti-tubulin (DM1A), anti-p-S6 (Ser235/236) (2F9), anti-p-S6
(Ser235/236) (D57.2.2E), anti-p-mTOR (Ser2448) (MRRBY), anti-mouse IgG
IRDye680, and anti-rabbit IgG IRDye800.
Mice. Breeding and maintenance of SPF mice were performed in the animal
facilities of the Department of Biomedicine (University of Basel, Switzerland) and
the Institute for Pharmacology and Toxicology (University of Veterinary Medicine
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Vienna, Austria; license: BMWFW-68.205/0093-WF/V/3b/2015). Germ-free (GF)
mice and gnotobiotic sDMDMm2 mice were bred at the Clean Mouse Facility
(University of Bern, Switzerland). GF mice were kept in flexible-film isolators or in
individually ventilated cages (IVC). Routine monitoring by culture-dependent and
-independent methods was done to confirm GF status. Gnotobiotic sDMDMm2
mice were generated by oral and rectal inoculation with a mixture of 12 bacterial
strains (see Table 1)26,41. All animal experiments were conducted according to the
Swiss Veterinary Law and Institutional Guidelines and were approved by the
Cantonal Veterinary Office Basel City. Male or female mice of 8-13 weeks of age
were used in all experiments. For all experiments, age- and sex-matched experi-
mental groups of mice were used. Mice were housed under pathogen-free condi-
tions in individually ventilated cages in a 22 °C temperature-controlled room with
12-h light–12-h dark cycles and free access to food and water. Experimental and
control mice were co-housed and euthanized by terminal CO2 inhalation.
Conventional C57BL/6 mice (WT) were purchased from Janvier Labs (Saint
Berthevin Cedex, France). The following transgenic mouse strains on C57BL/6
background were used: OT-II T-cell receptor transgenic (OT-IItg) mice (kindly
provided by Antonius Rolink, University of Basel, Switzerland)42, Rag2−/− mice
(kindly provided by Georg Hollaender, University of Basel, Switzerland and Jesus
College Oxford, UK)43, Rag1−/− mice, RORc(γt)-Cretg mice (kindly provided by
Andreas Diefenbach, Charité, Berlin, Germany)44, Rosa26ReYFP/+ (purchased from
The Jackson Laboratory, JAX: 006148)45, Il23p19−/− mice (kindly provided by B.
Becher, University of Zurich, Switzerland)46, Rag2−/−Il2rg−/− mice (kindly
provided by Joerg Kirberg, Paul-Ehrlich Institut, Langen, Germany)47, Flt3Ltg mice
(kindly provided by Antonius Rolink, University of Basel, Switzerland)48,Myd88fl/fl
mice (purchased from The Jackson Laboratory, JAX: 008888)49, and Ifng−/− mice
(kindly provided by Markus Heim, University of Basel, Switzerland)50. CD45.1+
mice (purchased from The Jackson Laboratory, JAX: 002014) were bred to
Rag2−/− mice.
To generate Rorγtfm+ mice, RORc(γt)-Cretg mice were bred to Rosa26ReYFP/+
mice, as published before44. In addition, Rorγtfm+ mice were bred to Rag2−/− mice
to generate Rorγtfm+Rag2−/− mice. RORc(γt)-Cretg mice were bred to Rptorfl/fl
mice (kindly provided by Michael N. Hall, University of Basel, Switzerland)51 and
backcrossed to Rag2−/− background to generate RptorILC3−/− mice. VAV1-Cretg
mice52 were bred to Stat3fl/fl mice53 to generate VAV1-CretgStat3fl/fl mice. RORc
(γt)-Cretg mice were bred to Myd88fl/fl mice to generate Myd88ILC3−/− mice.
Isolation of cells. SP and SI cells were isolated as published before14. In brief, the
SI was opened longitudinally, incubated with 30 mM EDTA in 1 x PBS and washed
several times with 1 x PBS to remove feces and mucus. Tissue pieces were digested
in DMEM (Thermo Fisher Scientific) containing 0.025 mg per mL DNase I (Sigma-
Aldrich) and 1 mg per mL collagenase D (Sigma-Aldrich) for 15 min at 37 °C.
Supernatant was collected after washing with DMEM. Digestion steps were repe-
ated three times with remaining tissue. After digestion SI cells were purified by
Percoll density gradient (40/80%) centrifugation. The SP was cut into pieces and
digested as the SI with DMEM containing DNase I and Collagenase D in 4 steps,
each 15 min at 37 °C. Afterwards erythrolysis was performed.
Bone marrow-derived dendritic cells (BMDCs) were generated as published
before14. In brief, femur and tibia were crushed. After erythrolysis bone marrow
cells were cultured with Fms-related tyrosine kinase 3 ligand (Flt3lg)54 (kindly
provided by Antonius Rolink, University of Basel, Switzerland) for 7 days at 37 °C,
10% CO2.
OT-IItg CD4+ T cells were isolated from secondary lymphoid organs as
described elsewhere14. In brief, suspensions of SP and lymph nodes were generated
and erythrolysis was performed. CD4+ cells were enriched with CD4 Microbeads
(Miltenyi Biotec) according to manufacturer’s instructions. To obtain a pure CD4+
T-cell population, CD11c−CD4+ T cells were sort-purified after enrichment.
Sorted CD4+ T cells were stained with 7.5 µM Carboxyfluorescein succinimidyl
ester (CFSE, Molecular Probes) at room temperature (10 min) and used for Ag
presentation assays.
Flow cytometry and cell sorting. Flow cytometry and cell sorting were done
according to standard protocols. Single-cell suspensions were incubated with anti-
FcγRII/RIII (cell culture supernatant of hybridoma cells producing clone 2.4G255
(kindly provided by Hans Acha-Orbea, University of Lausanne, Switzerland) and
surface marker-specific Ab for 30 min on ice in 1 x PBS containing 3% FBS. Live/
dead staining was done with the fixable viability dyes eFluor 450 (eBioscience) or
Zombie AquaTM (BioLegend). For intracellular RORγt staining cells were fixed and
permeabilized with the FoxP3 transcription factor staining buffer set (eBioscience)
according to manufacturer’s instructions. Cytokine staining was done after fixation
with PBS containing 4% paraformaldehyde for 10 min on ice. For staining of p-
STAT3 (Tyr705), p-mTOR (Ser2448) or p-S6 (Ser235/236) cells were fixed in PBS
containing 4% paraformaldehyde for 15 min at 37 °C directly after stimulation.
Permeabilization was done with True-Phos™ Perm Buffer (BioLegend) according to
manufacturer’s instructions. Afterward staining was done for 30 min on ice.
Annexin V staining was done with Annexin V APC (BD Biosciences) according
to manufacturer’s instructions.
To isolate NCR− ILC3s by cell sorting, SP and SI cells were stained with Abs
specific for CD117, Thy1.2, KLRG1 and a lineage cocktail (lin) of Abs. Unless
stated otherwise the following Abs were used for the lin cocktail: CD3ε, CD8α,
CD11b, CD11c, CD19, B220, Gr-1, TCR-β, TCR-γ/δ, TER-119, NK1.1, and
NKp46. To isolate MHC II+ cells, additional staining with MHC II Ab was done.
Data were acquired with FACS Canto II (BD Bioscience), LSR Fortessa (BD
Bioscience), or CytoFLEX (Beckman Coulter’s). Sorting was done with a FACS
Aria II (BD Bioscience). Diva Software (BD FACS Aria II, BD LSR Fortessa and BD
FACS Canto II) and CytExpert Software (CytoFLEX, Beckman Coulter) were used
for data collection. For analysis FlowJo (Tree Star) software was used.
Culture and stimulation of ILC3s. Cell culture was performed in IMDM medium
(IMDM powder, Sigma-Aldrich), containing 3.02 g per L NaHCO3 (Sigma-
Aldrich), 1% Penicillin Streptomycin (Thermo Fisher Scientific), 1% Ciproxine
Perfusion 0.2 g (Bayer), 0.1% Kanamycin (Sigma-Aldrich), 1% Insulin Transferrin
Selenium (Thermo Fisher Scientific), 0.3% Primatone (Sigma-Aldrich), 1% MEM-
NEAA (Thermo Fisher Scientific), 0.1% 2-mercaptoethanol (Thermo Fisher Sci-
entific), and 5% FBS. Sort-purified SI ILC3s (CD117+lin−Thy1.2+KLRG1−) were
cultured at 37 °C, 10% CO2 for 7 days with 5% supernatant of IL-2 secreting cell
line X63Ag8.65356 (kindly provided by Antonius Rolink, University of Basel,
Switzerland), IL-7 (30 ng per mL, Preprotech), SCF (20 ng per mL, Preprotech), 0.5
µg per mL Amphotericin B (Sigma-Aldrich), and 2% penicillin streptomycin
solution (Thermo Fisher Scientific) in 24-well plates (0.5–1 × 106 cells per well).
Medium was replaced by IMDM medium without Amphotericin B the next day.
To analyse in vitro downregulation of MHC II and CD74 ILC3s were exposed to
20 ng per mL IL-23 (eBioscience) for 7 days at 37 °C, 10% CO2 in addition to IL-2,
IL-7, and SCF. Fresh IL-23 was added every 2–3 days.
For analysis of Ciita promoter usage, MHC II expression and T-cell stimulation
capacity NCR− ILC3s (CD117+lin−Thy1.2+KLRG1−) were sort-purified from the
SI and incubated in 24-well plates (0.5–1 × 106 cells per well) with 20 ng per mL
IFN-γ (eBioscience) for 48 h or 120 h without additional cytokines at 37 °C, 10%
CO2. Combined stimulation with IFN-γ (20 ng per mL) and IL-23 (20 ng per mL)
was done for 120 h without additional cytokines at 37 °C, 10% CO2.
For phospho-flow staining sort-purified NCR− ILC3s (CD117+lin−Thy1.2+
KLRG1−) were stimulated for the indicated time points with or without IL-23 (20
ng per mL) or IL-1β (20 ng per mL) in IMDM medium. To analyse Ciita promoter
usage or induction of OX40L, ILC3s (CD117+lin−Thy1.2+KLRG1−) were isolated
from Rag2−/− mice and stimulated for 18 h with IL-23 (20 ng per mL) or IL-1β (20
ng per mL) in IMDM medium.
Antigen presentation assay. ILC3s or in vitro generated BMDCs were stimulated
overnight with 20 ng per mL IL-1β (Biovison Inc.). Unless otherwise indicated 5 ×
104 ILC3s or BMDCs were cultured with 1.5 × 105 CFSE-labeled OT-IItg CD4+
T cells in the presence of Ova protein (100 µg per mL, Imject Ovalbumin, Thermo
Fig. 7 IFN-γ positively regulates MHC II expression of ILC3s. a Normalized expression of Ciita mRNA isoforms regulated by promoters pI (n= 5 distinct
SP ILC3 samples and n= 9 distinct SI ILC3 samples), pIII (n= 5 distinct SP ILC3 samples and n= 9 distinct SI ILC3 samples), and pIV (n= 5 distinct SP
ILC3 samples and n= 8 distinct SI ILC3 samples) in SP and SI ILC3s. ILC3s were sorted as depicted in Supplementary Fig. 2a. Five independent
experiments. b Expression of IFN-γ in the SP and the SI of WT mice. n= 5 mice of two independent experiments. c MHC II expression of SI ILC3s fromWT
(n= 6 distinct samples) and Ifng−/− (n= 6 distinct samples) mice. NCR− ILC3s were gated as shown in Fig. 1. Two independent experiments. d MHC II
expression of SI ILC3s (Rag2−/−) stimulated for 48 h (n= 9 distinct samples of three independent experiments) or 120 h (n= 10 (w/o) distinct samples
and n= 11 (IFN-γ stimulated) distinct samples of four independent experiments) with or without (w/o) IFN-γ. ILC3s were sorted as depicted in
Supplementary Fig. 2a. e Normalized expression of Ciita mRNA isoform regulated by promoter pIV in SI ILC3s stimulated with or w/o IFN-γ for 120 h. n= 5
distinct samples of five independent experiments. ILC3s were sorted as depicted in Supplementary Fig. 2a. f SI ILC3s (sorted from Rag2−/− as depicted in
Supplementary Fig. 2a) were stimulated for 120 h with or w/o IFN-γ. Naive CFSE-labeled OT-IItg CD4+ T cells were cultured with 1 × 104 IFN-γ stimulated
or unstimulated ILC3s in the presence of Ova peptide. n= 7 distinct samples of three independent experiments. Each symbol represents a sample and the
bar graph represents the mean ± s.e.m. n.s., not significant; *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001, calculated with two-tailed unpaired
Student’s t test (a Ciita pI and pIII, b, c, and e), Mann–Whitney test (a Ciita pIV) or with mixed-effects models (two-sided) using lmerTest (d and f). Source
data are provided as a Source Data File.
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Fisher Scientific, Inc.) or Ova323-339 peptide (5 µg per mL, AnaSpec) or medium
alone for 72 h at 37 °C, 10% CO2. T cells were gated as CD3ε+ or CD117−; cells.
Eα-GFP assay. TOP10 E. coli bacteria were transformed with a plasmid (kindly
provided by Marc Jenkins, University of Minnesota, USA) encoding His-tagged
Eα-GFP57. After expansion and lysis of bacteria, the protein was purified with a
nickel column (His-Select Nickel Affinity Gel, Sigma-Aldrich) according to
manufacturer’s instructions. Purity was controlled by polyacrylamid gel
electrophoresis.
To analyse processing of Eα-GFP sort-purified NCR− ILC3s (CD117+lin−
Thy1.2+KLRG1−) from SP and SI were incubated with 100 µg per mL Eα-GFP
protein in 96-well plates for 72 h at 37 °C, 10% CO2. Surface presentation of Eα52-68
peptide was analyzed by flow cytometry with the YAe antibody (ebioYAe).
Adoptive cell transfer. Lin−Thy1.2+eYFP+ ILC3s of SP and SI were isolated from
RORγtfm+Rag2−/− mice. 0.5–1 × 106 SI ILC3s and 1–2 × 105 SP ILC3s were intra-
venously (i.v.) injected into Rag2−/−Il2rg−/− mice. Five weeks after transfer SP and
SI cells were isolated and analyzed by flow cytometry. For short-term migration
assays (7 days), total splenocytes or total SI lymphocytes from Rorγtfm+Rag2−/−
mice were isolated following our protocols described before and i.v. injected into
Rag2−/−Il2rg−/− mice (1 × 107 SI cells or 5 × 107 SP cells per mouse). Lin−Thy1.2+
KLRG1−eYFP+MHC II+ and Lin−Thy1.2+KLRG1−CD45.1+MHC II− ILC3s
were sort-purified from the SI of Rorγtfm+Rag2−/− and CD45.1+Rag2−/− mice,
respectively. 1–2 × 105 MHC II+ and MHC II− ILC3s were i.v. injected into
Rag2−/−Il2rg−/− mice in a ratio of ~1:1. Five weeks after transfer SP and SI cells
were isolated and analyzed by flow cytometry.
RNA sequencing. Cell suspensions were generated from SP and SI of RORγtfm+
mice. For T- and B-cell depletion of splenocytes 1 × 107 cells per mL were stained
with CD3ε-biotin and B220-biotin Abs for 15min on ice in PBS containing 3% FBS.
Afterward, cells were incubated with Streptavidin Microbeads (Miltenyi Biotec) for
15min on ice and depleted according to manufacturer’s instructions. CD117+lin−
Thy1.2+eYFP+ NCR− ILC3s were sort-purified from SI and SP suspensions. RNA
was isolated from 1–2 × 104 SP ILC3s and 0.5–3 × 105 SI ILC3s per sample with the
PicoPure RNA isolation kit (Thermo Fisher Scientific) according to manufacturer’s
instructions. For each sample biological triplicates were generated.
Rag2−/− mice were used for RNA sequencing of cultured ILC3s. CD117+
Thy1.2+lin−(CD3ε, CD8α, CD11b, CD11c, CD19, B220, Gr-1, TCR-β, TCR-γ/δ,
TER119, NK1.1)KLRG1− ILC3s were sort-purified from SI and cultured for 7 days,
as described above. RNA was isolated from cultured SI ILC3s (ca. 1 × 105 ILC3s per
sample) and freshly isolated CD117+lin−Thy1.2+KLRG1− ILC3s of SP (0.2–0.5 ×
105 ILC3s per sample) and SI (ca. 1 × 105 ILC3s per sample) with the PicoPure
RNA isolation kit (Thermo Fisher Scientific). For each sample biological replicates
were generated. RNA sequencing and quality control were done by the genomics
facility of the Friedrich Miescher Institute for Biomedical Research (Basel,
Switzerland) using Hiseq 2500 system. Total RNA was amplified with NuGEN
Ovation RNA Seq System V2. Library preparation was done with Illumina TruSeq
DNA Nano kit, according to manufacturer’s instructions. Base calling and quality
scoring were performed using RTA software (Real-Time Analysis).
Obtained single-end RNA-seq reads were mapped to the mouse genome
assembly, version mm9 (downloaded from genome.ucsc.edu), with RNA-STAR
(2.5.0c)58, with default parameters except for reporting for multi-mappers only one
hit in the final alignment files (outFilterMultimapNmax=1) and filtering reads
without evidence in spliced junction table (outFilterType=“BySJout”). Subsequent
gene expression data analysis was done within the R software (R Foundation for
Statistical Computing, Vienna, Austria). Raw reads and mapping quality was
assessed by the qQCreport function from the R/Bioconductor software package
QuasR (version 1.14.0)59.
Using RefSeq mRNA coordinates from UCSC (genome.ucsc.edu, down-
loaded in July 2013) and the qCount function from QuasR package, we
quantified gene expression as the number of reads that started within any
annotated exon of a gene. The differentially expressed genes were identified
using the edgeR package (version 3.16.5)60. Pools of mice (indicated as a factor)
were included as a covariate. Genes with a false discovery rate (FDR) smaller
than 0.05 and minimum log2 (fold change) of 1.5 were considered as
differentially expressed.
qRT PCR. For RNA isolation, tissue samples from duodenum, jejunum and terminal
ileum of the SI and the whole SP were directly frozen in TRIzol (TRI Reagent, Thermo
Fisher Scientific) in liquid N2. Homogenization of tissue was done in microtubes
containing Zirconia beads (BioSpec Products) using FastPrep-24 instrument (MP
Biomedicals) for 1min at 6.5m/s. RNA was isolated according to manufacturer’s
instructions (TRi Reagent, Thermo Fisher Scientific). Quality and concentration were
measured with a Nanodrop 2000c (Thermo Fisher Scientific). RNA of duodenum,
jejunum, and ileum was pooled afterward, unless otherwise indicated.
Synthesis of the first-strand cDNA was done with Oligo dT (Promega), dNTPs
(Roche), random hexamers (Sigma-Aldrich), and Superscript III Reverse
Transcriptase (Invitrogen) according to manufacturer’s instructions. Quantitative
real-time PCR (qRT PCR) was done using Sensimix SYBR-Hi-Rox Kit (Bioline) on
a Rotor-Gene RG 3000A (Corbett Research). The following primer were used: Tbp
fw (GGCACCACCCCCTTGTACCCT), Tbp rv (ACGCAGTTGTCCGTGGCTC
T), Il12b fw (TGGGAGTACCCTGACTCCTG), Il12b rv (AGGAACGCACCTTTC
TGGTT), Tnfsf4 fw (ACTCTCTTCCTCTCCGGCAAA), Tnfsf4 rv (TTGCCCATC
CTCACATCTGG), Il23p19 fw (CACCAGCGGGACATATGAATCT), Il23p19 rv
(CACTGGATACGGGGCACATT), Ifng fw (CTGAGACAATGAACGCTACAC),
and Ifng rv (TTTCTTCCACATCTATGCCAC).
Gene expression was normalized to the gene encoding TATA box binding
protein (Tbp) using the comparative threshold cycle method (ΔCT).
To analyse the expression of pI, pIII, or pIV regulated Ciita mRNA isoforms
qRT PCR was done. SI and SP NCR− ILC3s (Thy1.2+lin−KLRG1−) were isolated
from Rag2−/− mice. RNA was isolated with the RNeasy Micro Kit (Qiagen)
according to manufacturer’s instructions. Quality control was done with a
Nanodrop 2000c. cDNA synthesis and qRT PCR were done as described above.
The following primer were used: Ciita pI fw (CAGGGACCATGGAGACCATA
GT), Ciita pI rv (CAGGTAGCTGCCCTCTGGAG), Ciita pIII fw (CTGCATCA
CTCTGCTCTCTAA), Ciita pIII rv (GTCATAGAGGTGGTAGAGATGT), Ciita
pIV fw (CATGCAGGCAGCACTCAGAA), and Ciita pIV rv (GGGTCGGCAT
CACTGTTAAGG). Rotor-Gene software (Corbett Research) was used for data
collection and analysis.
In-Cell Western. Sort-purified lin−CD90.2+KLRG1−SI LC3s from Flt3tg were
cultured 48 h with or without 20 ng per mL IL-23 in the presence or absence of
rapamycin (10 or 100 nM). After stimulation, the cells were fixed in PBS containing
3.75% paraformaldehyde for 30 min at room temperature and washed twice with
1% BSA in PBS. Then, cells were permeabilized for 30 min with 0.1% Triton X100
in 1% BSA/PBS and washed once. After blocking with 1% goat serum in 1% BSA/
PBS, cells were incubated overnight with primary mouse α-tubulin (Sigma-Aldrich)
and rabbit α-p-S6 Ser235/236 (Cell Signaling Technology) Abs. Finally, cells were
washed three times with 0.1% Triton X100 in 1% BSA/PBS, incubated for 1 h with
secondary goat α-mouse IgG IRDye680 (LI-COR Biosciences) and goat α-rabbit
IgG IRDye800 (LI-COR Biosciences) Abs and washed five times with 0.1% Triton
X100 in 1% BSA/PBS. Before scanning the cells with the Odyssey CLx Infrared
Scanning System (LI-COR Biosciences), all supernatant was removed. Image Stu-
dio Software (LI-COR) using Odyssey CLx Infrared Scanning System (LI-COR
Biosciences) was used for data collection.
Statistical analysis. GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA,
USA) was used to calculate P values with one-way ANOVA, Mann–Whitney test or
two-tailed Student’s t test with a 95% confidence interval, as outlined in each figure
legend. In some experiments pools of mice were used for in vitro assays. Statistical
analysis for these experiments was done with mixed-effects models (random effect:
pool of mice, fixed effect: treatment, mouse strain or organ) and lmerTest package
of R software with a Satterthwaite approximation61. For multiple comparisons with
mixed effect models P values have been adjusted with Benjamini–Hochberg
procedure.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing data reported in this paper is accessible with the following accession code:
GSE114751 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114751). Data
bases used in this study are accessible at UCSC Genome Browser (http://hgdownload.soe.
ucsc.edu/goldenPath/mm9/bigZips/, http://hgdownload.soe.ucsc.edu/goldenPath/mm9/
database/). The data underlying Figs. 1e, 2a–d, 3a, b, 4c–e, 5a–g, 6a–d, 7a–f and
Supplementary Figs. 2c, d, g, h, 3a, b, e, 4a, b, 5a, g, 6b, c, 7a–c and 8a, b are provided as a
Source Data File.
Code availability
Data analyses codes have been published before and are available from the corresponding
author on request58–60.
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